BACKGROUND: The aim of this study was to evaluate the clinical outcome of @entity1 with @entity4008 following the introduction of @entity619 treatment in Denmark. METHODS: Adult @entity1 with @entity4008 , admitted from 2003-2010 to two different university hospitals, were included retrospectively. Data at clinical presentation, Glasgow outcome scale (GOS), cerebrospinal fluid and blood biochemistry were collected. Relative risk (RR) with 95% confidence interval (CI) was computed by Cox proportional hazard regression analysis. RESULTS: One hundred and forty-seven @entity1 were included in the study. The population had a median age of 62 years and 31% had an immunosuppressive co-morbidity. Eighty-nine @entity1 had an unfavourable outcome (GOS score   =   1-4). Adjuvant treatment with @entity288 (RR   =   0.48; 95% CI   =   0.30-0.76) was associated with a favourable outcome (GOS score   =   5), while altered mental status (RR   =   2.36; 95% CI   =   1.17-4.78) and age (RR   =   1.03; 95% CI   =   1.01-1.04) per year increment was associated with an unfavourable outcome. Adjuvant @entity228 treatment did not affect short- or long-term survival. Short-term mortality was influenced by age (RR   =   1.06; 95% CI   =   1.04-1.09). Long-term mortality was influenced by age (RR   =   1.06; 95% CI   =   1.03-1.08) and female sex (RR   =   1.81; 95% CI   =   1.05-3.14). CONCLUSION: This study indicated that adjuvant @entity228 treatment in acute @entity4008 improves the outcome and can safely be administered in an elderly population with high levels of immunosuppressive co-morbidity.

Improved outcome of @entity4008 associated with use of XXXX treatment.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity4008 :: ('MESH:D016920', 'Disease') :: ['bacterial meningitis'] @entity228 :: ('CHEBI:50858', 'Chemical') :: ['corticosteroid'] @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone'] @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids']
@entity228 :: (CHEBI:50858,Chemical) :: ['corticosteroid']
